Physician profile
Binju Joel
NPI 1699817833
$1,278.08
in general payments reported to CMS, 2019-2025
14 companies · $393 in 2025
The $393 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $293 · 2023: $194 · 2024: $398 · 2025: $393.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $985.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $984.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tactile Systems Technology INC | $434.15 | 2023-2025 | Flexitouch Plus, Nimbl, Entre Plus |
| Pfizer INC. | $219.99 | 2022-2025 | |
| Lilly USA, LLC | $174.66 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Biohaven Pharmaceutical Holding Company LTD. | $79.76 | 2022 | |
| Exact Sciences Corporation | $75.41 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amgen INC. | $62.14 | 2022-2023 | Otezla, Repatha |
| Novo Nordisk INC | $57.64 | 2022-2025 | Wegovy |
| Rhythm Pharmaceuticals, INC. | $56.03 | 2022-2025 | Imcivree, Imcivree |
| Dexcom, INC. | $30.88 | 2024 | Dexcom G6 Transmitter |
| Cashflow Solutions, LLC | $25.61 | 2025 | Pcd-52 737a (US) White, Lympha Press Optimal Plus(US) Bt, Pcd-51 731a (US) - White |
| Idorsia Pharmaceuticals US INC | $18.53 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $16.32 | 2023 | Eliquis |
| Glaxosmithkline, LLC. | $15.17 | 2022 | |
| Ibsa Pharma INC. | $11.79 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Binju Joel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.